title: Safely treating hepatitis C in patients with HIV or hepatitis B virus coinfection.
abstract: BACKGROUND
  There are several clinical trials and prospective studies which support the use of direct-acting antiviral agents (DAAs) in hepatitis C virus (HCV)-coinfected patients. In this review, the safety of DAAs in HCV patients coinfected with hepatitis B virus (HBV) or HIV has been evaluated.
  
  
  METHODS
  All available prospective studies, clinical trials and congress abstracts in the English language that assessed the safety and efficacy of DAAs in HCV coinfections have been considered.
  
  
  CONCLUSIONS
  The newer DAAs in the treatment of HCV/HIV-coinfected patients resolved major limitations of the first-generation protease inhibitors including complex dosing, poor tolerability and interactions with antiretroviral drugs. There are not yet enough data regarding the safety and efficacy of DAAs in some coinfected patients with comorbidities, nor for pregnant, lactating or pediatric patients. Evaluating the safety and efficacy of these agents in these subgroups with HCV coinfection is recommended for future studies. The role of new direct-acting antiviral-based therapy for the treatment of patients with HCV/HBV coinfection remains to be evaluated.
authors: Tehran University of Medical Sciences, Department of Clinical Pharmacy, Faculty of Pharmacy , Tehran , Iran.
authors: Atefeh
authors: A
authors: Jafari
authors: Hossein
authors: H
authors: Khalili
authors: Mandana
authors: M
authors: Izadpanah
authors: Simin
authors: S
authors: Dashti-Khavidaki
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D060085:Coinfection; D004347:Drug Interactions; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D011480:Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D000998:Antiviral Agents; D011480:Protease Inhibitors
keywords: HIV; coinfection; hepatitis B virus; hepatitis C virus